AUTOIMMUNE INFLAMMATORY ARTHRITIS · SEROPOSITIVE AND SERONEGATIVE RA
A physician-led, laboratory-verified treatment programme targeting the immunological and inflammatory mechanisms of joint destruction — tailored to the individual disease activity, serological profile and functional status of each RA patient.
Request Medical ConsultationAbout the Condition
Rheumatoid Arthritis (RA) is a chronic autoimmune disease in which the immune system attacks the synovial lining of the joints, triggering persistent inflammation, cartilage erosion and progressive bone destruction. Unlike osteoarthritis, RA is driven by immune dysregulation — not mechanical wear.
The disease typically presents with symmetrical joint involvement, morning stiffness lasting over 30 minutes, and progressive loss of grip strength and hand function. Extra-articular manifestations — including fatigue, low-grade fever, rheumatoid nodules and systemic inflammation — affect the majority of patients over time.
RA affects approximately 0.5–1% of the global population, with a 3:1 female-to-male ratio. Standard treatment relies on DMARDs and biologics that suppress immune activity broadly. Our programme targets the specific immunological pathways driving joint destruction — offering a complementary biological approach where conventional therapy provides insufficient control.
Seropositive RA (RF+/anti-CCP+)
The most common and typically more aggressive form, characterised by the presence of rheumatoid factor (RF) and/or anti-citrullinated protein antibodies (anti-CCP). Associated with higher rates of joint erosion, extra-articular complications and disease progression. Accounts for approximately 60–80% of RA diagnoses.
Seronegative RA
RA diagnosed in the absence of detectable RF and anti-CCP antibodies. Can be equally destructive but is often diagnosed later due to negative serological markers. Requires clinical and imaging-based confirmation. Represents approximately 20–40% of RA cases.
Juvenile Idiopathic Arthritis (JIA)
Autoimmune arthritis with onset before age 16. Multiple subtypes exist, including polyarticular JIA which closely resembles adult RA. Early intervention is critical to prevent growth disturbance and permanent joint damage. Affects approximately 1 in 1,000 children.
Palindromic Rheumatism progressing to RA
Episodic joint inflammation with symptom-free intervals that, in approximately 30–50% of cases, evolves into established RA. Early identification of this progression pattern allows timely therapeutic intervention before irreversible erosive changes develop.
Our program is individually adapted for all subtypes and all stages of progression.
Important: Each patient is accepted into the programme only after a comprehensive individual medical assessment, which evaluates serological status, disease activity (DAS28), functional capacity (HAQ-DI), imaging findings and overall clinical profile.
We do not offer a cure for RA. Our programme targets the immunological mechanisms driving chronic synovial inflammation and joint destruction — with the clinical objective of reducing disease activity, preserving joint function and improving daily quality of life.
Clinical Outcomes
The following data are derived from structured observational analysis of RA patients treated at BioCells Medical between 2016 and 2025. All figures represent aggregated clinical registry outcomes with longitudinal follow-up. These are observational results — not randomised controlled trial data — and do not constitute a guarantee of therapeutic effect.
46
RA patients treated
78%
demonstrated measurable reduction in disease activity within 2–5 months
72%
achieved clinically significant DAS28 score reduction
65%
reported meaningful improvement in HAQ-DI functional scores
−1.4
average DAS28 score reduction at 5-month follow-up
61%
maintained improved disease activity status — follow-up to 2 years
Reduced morning stiffness duration and severity
74%
Improved grip strength and hand function
68%
Decreased number of swollen and tender joints
71%
Reduction in systemic inflammatory markers (CRP, ESR)
63%
Reduced analgesic and corticosteroid requirement
56%
2–6 weeks
Initial functional response
2–5 months
Clinically meaningful change
1–2 years under continued monitoring
Sustained disease activity control
Important: Outcomes depend on RA subtype, baseline DAS28 score, disease duration, prior treatment history and individual biological response. Individual results may vary significantly.
Find out if our program can help in your specific case. The initial medical consultation is free and carries no obligation.
Request ConsultationPatient Stories
“Mornings used to take two hours before my hands would cooperate. I could not open a jar or button a shirt. Three months after the programme, the stiffness dropped to twenty minutes. My rheumatologist confirmed the swelling went down. She asked what changed. I still take methotrexate, but at half the dose.”
Patient
Seropositive RA · Germany
Every case is assessed individually by our physician team. Request a consultation to discuss your specific situation with our physician team.
Request ConsultationThe BioCells Program
Our RA programme combines five biological components into a single personalised protocol. No two protocols are identical — each is constructed following a detailed medical evaluation of the patient's immunological profile, disease activity and clinical priorities.
No surgery required
Treatment is delivered by intravenous infusion or targeted intra-articular injection — not surgical instruments.
No general anaesthesia
All procedures are performed under local anaesthesia or without anaesthesia entirely. No hospitalisation required.
No risk of immune rejection — autologous option
Where clinically appropriate, we use the patient's own cells. Zero risk of graft-versus-host disease with autologous protocols.
Targets the immunological drivers, not just symptoms
Our protocol addresses synovial inflammation, immune dysregulation and cytokine imbalance — the biological mechanisms behind joint destruction in RA.
Complements existing medication
Our programme is compatible with methotrexate, biologics and other current DMARDs. Patients do not need to discontinue existing treatment before commencing our protocol.
Treatment at your location worldwide
Our medical team is available to conduct treatment at our Warsaw clinic or to travel to the patient's location anywhere in the world.
What It Is
MSCs are multipotent regenerative cells with established immunomodulatory and anti-inflammatory properties. They are among the most extensively studied cell types in autoimmune and inflammatory disease research, with a strong safety profile across thousands of clinical applications.
How It Is Done
Cells are collected from the patient's own bone marrow (autologous, approximately 50 ml under local anaesthesia) or sourced from a certified donor (allogeneic), depending on individual clinical indications. All cells are expanded, quality-controlled and tested in our certified Warsaw laboratory before administration.
Biological Mechanisms
How This Helps in Rheumatoid Arthritis
In RA, the synovial membrane becomes a site of persistent immune-mediated inflammation, leading to pannus formation and progressive cartilage and bone erosion. MSCs directly address this by suppressing pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β), shifting the local immune environment from destructive to reparative, and providing biological signals that support cartilage preservation.
Your Medical Board
The exact combination, dosage, sequencing and delivery method of all five components is determined individually by our medical board for each patient. No two treatment protocols are identical. Your programme is constructed based on your specific diagnosis, serological status, disease activity scores, joint involvement pattern and clinical priorities.
Your protocol is designed individually. Speak with our medical team to understand what your personalised program would include.
Request ConsultationPatient Journey
Your case is reviewed remotely by our physician team. We assess your diagnosis, current DAS28 status, medication history and treatment goals. This consultation is free and carries no obligation.
A detailed review of all medical documentation, including serological markers, imaging and functional assessments. Our medical board evaluates eligibility, confirms safety parameters and designs your personalised therapeutic protocol.
Your cells are collected, isolated, expanded and quality-tested in our certified Warsaw laboratory. Each batch receives a full traceability certificate. This stage typically takes 2–3 weeks.
Cells are delivered by intravenous infusion or targeted intra-articular administration — no surgery, no general anaesthesia. Treatment is available at our Warsaw clinic or with our medical team at your location worldwide. Airport transfers, accommodation and visa support are included in the programme. Where clinically appropriate, our medical board may approve a travelling treatment programme — our medical team flies directly to the patient.
Structured rehabilitation sessions with our specialist, adapted to your current joint function and inflammatory status. Includes joint-specific physiotherapy, range-of-motion protocols and guidance on activity modification. Available at our clinic or remotely coordinated with your local medical team.
Your dedicated coordinator monitors disease activity, functional status and inflammatory markers. A medical-grade wearable bracelet supports continuous health tracking regardless of your location. DAS28 and HAQ-DI reassessments are scheduled at defined intervals.
The first step is free. Request a medical consultation and our medical consultant will contact you within 24 hours.
Request ConsultationSafety Profile
Cellular therapy is considered safe when delivered under proper medical supervision and according to validated protocols. In our practice, the procedure is well-tolerated by the majority of RA patients.
Temporary mild reactions — such as transient local discomfort at the infusion or injection site, slight fatigue or low-grade temperature — may occur in a minority of patients. These are typically short-lived and indicate active immune engagement.
A final medical assessment is performed on-site before every treatment session. If a patient's inflammatory status has changed significantly — including acute flare — the programme may be temporarily modified or postponed for safety reasons.
All contraindications are evaluated individually. A contraindication in one clinical context does not necessarily preclude treatment in a different context — this is always determined by physician assessment.
Standard Contraindications
Active acute infection or fever
Active malignancy or ongoing chemotherapy / radiotherapy
Severe decompensated cardiac or renal failure
Pregnancy
Post-Treatment
Dedicated rheumatology-trained coordinator
monitors disease activity, joint function and inflammatory markers
Personalised rehabilitation programme
joint-specific physiotherapy adapted to your functional capacity and flare pattern
Medical-grade wearable monitoring
continuous physiological data collection supporting clinical decision-making
Long-term coordinator support
proactive check-ins, DAS28 reassessments and response to any changes in disease activity
Continued clinical access
our medical team remains available for ongoing reassessment and protocol adjustment
Immunological remodelling is a gradual biological process. The post-treatment period requires structured monitoring, periodic reassessment and — where indicated — protocol adjustment based on objective disease activity data.
Get Started
If you or someone you love has been diagnosed with rheumatoid arthritis, our medical team is available for a free, no-obligation medical consultation — based on your diagnosis, current disease activity and individual clinical profile.
We review every inquiry personally. You will speak with a physician, not an administrator.
Submit your case online or by phone
Our medical consultant contacts you to review your documents
The medical board presents your personalised treatment plan
Request a Consultation
Tell us about your condition. Our medical consultant will contact you within 24 hours to review your documents.
Open Consultation FormMultilingual coordination — English, Italian, French, Russian, Polish
Evidence Base
Our clinical approach is informed by and consistent with published research in the field of regenerative medicine.
